Full-Time

Senior Forward Deployed Engineer

AI Studio

Updated on 9/9/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$156.2k - $211.3k/yr

+ Annual bonus + Stock-based long-term incentives

Remote in USA

Remote

Bachelor's, Master's, PhD

Category
Software Engineering (1)
Required Skills
LLM
Kubernetes
MLOps
Python
JavaScript
Airflow
Apache Spark
SQL
Machine Learning
MLflow
Data Engineering
Infrastructure as Code (IaC)
RAG
TypeScript
AWS
Observability
REST APIs
DevOps
Computer Vision
Databricks

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree and 1 year of experience in Computer Science, IT, or a related field, or a master's degree with 8–10 years of experience, or a bachelor's degree with 10–12 years of experience, or a diploma with 12–14 years of experience.
  • Technical discovery and value framing experience, including workflow analysis, intended-use definition, feasibility assessment, data and integration readiness, success measures, estimates, dependency mapping, and technical go/no-go recommendations.
  • Enterprise solution architecture and integration experience across applications, APIs, services, data and knowledge flows, models, retrieval, agents, workflows, persistence, identity, security zones, enterprise systems, and support boundaries.
  • Production proficiency in Python and SQL, with experience designing or reviewing production software, APIs, services, data flows, evaluation pipelines, and enterprise integrations.
  • End-to-end technical ownership of at least one production AI, machine learning, software, data, or automation solution that delivered a measurable enterprise outcome.
  • Ability to turn complex business problems into coherent technical designs, executable delivery plans, acceptance criteria, and production-readiness evidence while coordinating multidisciplinary teams.
  • Advanced capability in at least one role-defining pillar: applied AI or machine learning, generative AI/retrieval-augmented generation/agents, full-stack and integration engineering, or AI platform/MLOps, plus breadth across the production lifecycle.
  • Experience with advanced retrieval-augmented generation, knowledge, and agent systems, including hybrid or graph retrieval, knowledge graphs, source verification, MCP-style integration, durable or multi-agent workflows, policy enforcement, and adversarial testing.
  • Strong hands-on proficiency in Python and SQL.
  • Ability to provide strong technical leadership through influence, credibility, constructive challenge, and hands-on problem solving.
  • Ability to clearly communicate evidence, uncertainty, risks, trade-offs, limitations, and delivery status to diverse audiences.
  • Sound judgment, ownership, and resilience when balancing value, speed, quality, security, compliance, cost, maintainability, and supportability across global teams.
Responsibilities
  • Lead discovery by clarifying the business workflow, users, intended outcome, value hypothesis, acceptance criteria, operational constraints, data readiness, integration dependencies, and production implications.
  • Translate complex problems into an executable solution design, delivery plan, technical workstreams, estimates, milestones, dependencies, risks, acceptance criteria, release approach, and support transition.
  • Build, prototype, review, or contribute to critical production components, including AI-enabled applications, retrieval-augmented generation, bounded agents, intelligent automation, APIs, and integrations.
  • Define and maintain integrated architecture across applications, workflows, data and knowledge pipelines, models, retrieval, agents, APIs, enterprise integrations, identity, access controls, observability, and human review.
  • Orchestrate delivery across full-stack engineering, data science, machine learning and context engineering, testing, platform, security, compliance, and business roles.
  • Establish integrated testing, AI evaluation, and governance covering functional, performance, security, data, model, retrieval, generation, tool use, human oversight, and operational behavior with explicit release thresholds.
  • Coordinate production readiness through continuous integration and continuous delivery, staged release, monitoring, logging, service-level objectives, rollback, recovery, runbooks, and controlled deployment.
  • Support early issue triage, stabilization, and transition to the operating owner.
  • Communicate evidence, risks, trade-offs, and status; measure adoption and value; and convert delivery lessons into reusable components, accelerators, standards, documentation, and playbooks.
Desired Qualifications
  • Experience with classical machine learning and natural language processing.
  • Experience with foundation-model integration, prompt and context management, structured output, provenance, citations, bounded tool use, permissions, recovery, and human control.
  • Experience with representative evidence, baselines, gold sets, error taxonomies, expert adjudication, model and retrieval quality, task success, safety, latency, reliability, failure analysis, responsible artificial intelligence, privacy, validation, auditability, and GxP controls.
  • Experience with cloud-native services, containers, continuous integration and continuous delivery, infrastructure as code, versioning, observability, service-level objectives, staged release, rollback, incidents, disaster recovery, capacity, FinOps, runbooks, and MLOps/LLMOps.
  • Experience with AWS, Bedrock or SageMaker, Databricks, Spark, Kubernetes, serverless or event-driven systems, infrastructure as code, MLflow, Airflow, Kubeflow, observability, and FinOps.
  • Experience with JavaScript or TypeScript, modern web applications, API gateways, distributed workflows, process automation, document or vision capabilities, and human-AI review experiences.
  • Life sciences, biotechnology, pharmaceutical, healthcare, GxP, or validated-system experience.
  • Experience developing reusable frameworks, accelerators, standards, platform capabilities, and mentoring.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.